Home LiteratureArticle Details
PMID: 18263627 Published · ppublish English Comparative Study Evaluation Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Brain : a journal of neurology ·Vol. 131 ·No. Pt 3 ·2008-03-00 ·Pages 665-80

Jack CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC

Abstract

To date, most diagnostic imaging comparisons between amyloid labelling ligands and other imaging modalities have been between the use of amyloid labelling ligand (11)C Pittsburgh Compound B (PiB) and FDG-PET. Our objectives were to compare cognitive performance and diagnostic group-wise discrimination between cognitively normal, amnestic mild cognitive impairment (MCI) and Alzheimer's disease subjects with MRI-based measures of hippocampal volume and PiB retention, and secondly to evaluate the topographic distribution of PiB retention and grey matter loss using 3D voxel-wise methods. Twenty cognitively normal, 17 amnestic MCI and 8 probable Alzheimer's disease subjects were imaged with both MRI and PiB. PiB retention was quantified as the ratio of uptake in cortical to cerebellar regions of interest (ROIs) 40-60 min post-injection. A global cortical PiB retention summary measure was derived from six cortical ROIs. Statistical parametric mapping (SPM) and voxel-based morphometry (VBM) were used to evaluate PiB retention and grey matter loss on a 3D voxel-wise basis. Alzheimer's disease subjects had high global cortical PiB retention and low hippocampal volume; most cognitively normal subjects had low PiB retention and high hippocampal volume; and on average amnestic MCI subjects were intermediate on both PiB and hippocampal volume. A target-to-cerebellar ratio of 1.5 was used to designate subjects with high or low PiB cortical retention. All Alzheimer's disease subjects fell above this ratio, as did 6 out of 20 cognitively normal subjects and 9 out of 17 MCI subjects, indicating bi-modal PiB retention in the latter two groups. Interestingly, we found no consistent differences in learning and memory performance between high versus low PiB cognitively normal or amnestic MCI subjects. The SPM/VBM voxel-wise comparisons of Alzheimer's disease versus cognitively normal subjects provided complementary information in that clear and meaningful similarities and differences in topographical distribution of amyloid deposition and grey matter loss were shown. The frontal lobes had high PiB retention with little grey matter loss, anteromedial temporal areas had low PiB retention with significant grey matter loss, whereas lateral temporoparietal association cortex displayed both significant PiB retention and grey matter loss. A voxel-wise SPM conjunction analysis revealed that subjects with high PiB retention shared a common PiB retention topographical pattern regardless of clinical category, and this matched that of amyloid plaque distribution from autopsy studies of Alzheimer's disease. Both global cortical PiB retention and hippocampal volumes demonstrated significant correlation in the expected direction with cognitive testing performance; however, correlations were stronger with MRI than PiB. Pair-wise inter-group diagnostic separation was significant for all group-wise pairs for both PiB and hippocampal volume with the exception of the comparison of cognitively normal versus amnestic MCI, which was not significant for PiB. PiB and MRI provided complementary information such that clinical diagnostic classification using both methods was superior to using either in isolation.

MeSH Terms
Aged Alzheimer Disease/diagnosis,diagnostic imaging Amnesia/diagnosis,diagnostic imaging Aniline Compounds Brain Mapping/methods Carbon Radioisotopes Cognition Disorders/diagnosis,diagnostic imaging Diagnosis, Differential Female Hippocampus/diagnostic imaging,pathology Humans Longitudinal Studies Magnetic Resonance Imaging/methods Male Middle Aged Neuropsychological Tests Positron-Emission Tomography/methods Thiazoles
Chemicals
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole Aniline Compounds Carbon Radioisotopes Thiazoles
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Jack Clifford R
Department of Diagnostic Radiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA. [email protected]
Lowe Val J
Senjem Matthew L
Weigand Stephen D
Kemp Bradley J
Shiung Maria M
Knopman David S
Boeve Bradley F
Klunk William E
Mathis Chester A
Petersen Ronald C
References (81)
81 references, click to expand
  1. Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study.
    J Geriatr Psychiatry Neurol. 2005 Dec;18(4):224-7 PMID: 16306244
  2. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals.
    J Neuropathol Exp Neurol. 1998 Dec;57(12):1168-74 PMID: 9862640
  3. "Preclinical" AD revisited: neuropathology of cognitively normal older adults.
    Neurology. 2000 Aug 8;55(3):370-6 PMID: 10932270
  4. Neuropathology of cognitively normal elderly.
    J Neuropathol Exp Neurol. 2003 Nov;62(11):1087-95 PMID: 14656067
  5. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.
    Ann Neurol. 1991 Oct;30(4):572-80 PMID: 1789684
  6. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.
    J Psychiatr Res. 1975 Nov;12(3):189-98 PMID: 1202204
  7. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease.
    Neurology. 1998 Oct;51(4):993-9 PMID: 9781519
  8. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease.
    Ann Neurol. 1999 Mar;45(3):358-68 PMID: 10072051
  9. Pathological markers associated with normal aging and dementia in the elderly.
    Ann Neurol. 1993 Oct;34(4):566-73 PMID: 8215244
  10. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease.
    Neurology. 1997 Sep;49(3):786-94 PMID: 9305341
  11. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia.
    Neurology. 1997 May;48(5):1297-304 PMID: 9153461
  12. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study.
    JAMA. 1997 Mar 12;277(10):813-7 PMID: 9052711
  13. Neuropathological stageing of Alzheimer-related changes.
    Acta Neuropathol. 1991;82(4):239-59 PMID: 1759558
  14. Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy.
    J Neurosci. 2001 Feb 1;21(3):858-64 PMID: 11157072
  15. Thresholding of statistical maps in functional neuroimaging using the false discovery rate.
    Neuroimage. 2002 Apr;15(4):870-8 PMID: 11906227
  16. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study.
    Ann Neurol. 2006 Jul;60(1):145-7 PMID: 16802294
  17. Voxel-based morphometry--the methods.
    Neuroimage. 2000 Jun;11(6 Pt 1):805-21 PMID: 10860804
  18. Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment.
    Arch Neurol. 2003 Dec;60(12):1777-81 PMID: 14676056
  19. Changes in premorbid brain volume predict Alzheimer's disease pathology.
    Neurology. 2003 Aug 26;61(4):487-92 PMID: 12939422
  20. Automated template-based PET region of interest analyses in the aging brain.
    Neuroimage. 2007 Jan 15;34(2):608-17 PMID: 17112749
  21. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory.
    J Neurosci. 2005 Aug 24;25(34):7709-17 PMID: 16120771
  22. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia.
    Ann Neurol. 2005 Jun;57(6):896-903 PMID: 15929035
  23. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
    Ann Neurol. 2006 Mar;59(3):512-9 PMID: 16372280
  24. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques.
    Ann Neurol. 1988 Feb;23(2):138-44 PMID: 2897823
  25. Comparative evaluation of MR-based partial-volume correction schemes for PET.
    J Nucl Med. 1999 Dec;40(12):2053-65 PMID: 10616886
  26. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.
    J Med Chem. 2003 Jun 19;46(13):2740-54 PMID: 12801237
  27. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images.
    Lancet. 2001 Jul 21;358(9277):201-5 PMID: 11476837
  28. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain.
    Neuroimage. 2002 Jan;15(1):273-89 PMID: 11771995
  29. The Oregon brain aging study: neuropathology accompanying healthy aging in the oldest old.
    Neurology. 2000 Jan 11;54(1):105-13 PMID: 10636134
  30. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease.
    Neuroscience. 2000;95(3):721-5 PMID: 10670438
  31. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease.
    J Mol Neurosci. 2001 Oct;17(2):101-18 PMID: 11816784
  32. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI.
    Neurology. 2005 Oct 25;65(8):1227-31 PMID: 16247049
  33. Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry.
    J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):657-64 PMID: 12438466
  34. Early marker for Alzheimer's disease: the atrophic hippocampus.
    Lancet. 1989 Sep 16;2(8664):672-3 PMID: 2570916
  35. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.
    J Magn Reson Imaging. 2008 Apr;27(4):685-91 PMID: 18302232
  36. MRI of the hippocampus in Alzheimer's disease: sensitivity, specificity, and analysis of the incorrectly classified subjects.
    Neurobiol Aging. 1998 Jan-Feb;19(1):23-31 PMID: 9562499
  37. Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease.
    Neuroimage. 2005 Jun;26(2):600-8 PMID: 15907317
  38. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.
    Neurology. 2007 Apr 10;68(15):1205-12 PMID: 17420404
  39. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study.
    Neurology. 2002 May 28;58(10):1476-82 PMID: 12034782
  40. PET imaging of amyloid deposition in patients with mild cognitive impairment.
    Neurobiol Aging. 2008 Oct;29(10):1456-65 PMID: 17499392
  41. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.
    JAMA. 1995 Apr 26;273(16):1274-8 PMID: 7646655
  42. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease.
    Neurology. 1992 Jan;42(1):183-8 PMID: 1734300
  43. The short test of mental status. Correlations with standardized psychometric testing.
    Arch Neurol. 1991 Jul;48(7):725-8 PMID: 1859300
  44. Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study.
    Ann Neurol. 2002 May;51(5):567-77 PMID: 12112102
  45. MRI measures of entorhinal cortex vs hippocampus in preclinical AD.
    Neurology. 2002 Apr 23;58(8):1188-96 PMID: 11971085
  46. Mayo Clinic Alzheimer's Disease Patient Registry.
    Aging (Milano). 1990 Dec;2(4):408-15 PMID: 2094381
  47. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment.
    Neurology. 2008 Feb 12;70(7):512-20 PMID: 17898323
  48. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.
    Neurology. 2007 Feb 13;68(7):501-8 PMID: 17065593
  49. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.
    Neurology. 2007 May 8;68(19):1603-6 PMID: 17485647
  50. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease.
    Brain. 2007 Mar;130(Pt 3):708-19 PMID: 17267521
  51. Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects.
    Alzheimer Dis Assoc Disord. 2004 Oct-Dec;18(4):190-5 PMID: 15592129
  52. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.
    Brain. 2007 Nov;130(Pt 11):2837-44 PMID: 17928318
  53. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia.
    Neurology. 2002 Mar 12;58(5):750-7 PMID: 11889239
  54. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution.
    J Neuropathol Exp Neurol. 1993 Nov;52(6):594-600 PMID: 8229078
  55. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.
    Neurology. 2006 Aug 8;67(3):446-52 PMID: 16894106
  56. PET of brain amyloid and tau in mild cognitive impairment.
    N Engl J Med. 2006 Dec 21;355(25):2652-63 PMID: 17182990
  57. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
    Neurology. 1984 Jul;34(7):939-44 PMID: 6610841
  58. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.
    Neurology. 1999 Apr 22;52(7):1397-403 PMID: 10227624
  59. Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease.
    Neurosci Lett. 2000 May 19;285(3):231-3 PMID: 10806328
  60. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment.
    J Neurol. 1999 Jun;246(6):477-85 PMID: 10431775
  61. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.
    Arch Neurol. 2007 Mar;64(3):431-4 PMID: 17353389
  62. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study.
    Brain. 1996 Dec;119 ( Pt 6):2001-7 PMID: 9010004
  63. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease.
    Arch Neurol. 1993 Sep;50(9):949-54 PMID: 8363449
  64. Imaging beta-amyloid burden in aging and dementia.
    Neurology. 2007 May 15;68(20):1718-25 PMID: 17502554
  65. Valid conjunction inference with the minimum statistic.
    Neuroimage. 2005 Apr 15;25(3):653-60 PMID: 15808966
  66. Current concepts in mild cognitive impairment.
    Arch Neurol. 2001 Dec;58(12):1985-92 PMID: 11735772
  67. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.
    J Nucl Med. 2005 Dec;46(12):1959-72 PMID: 16330558
  68. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET.
    Am J Geriatr Psychiatry. 2004 Nov-Dec;12(6):584-95 PMID: 15545326
  69. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease.
    Neurology. 2006 Nov 14;67(9):1575-80 PMID: 16971697
  70. Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults.
    Radiology. 1989 Aug;172(2):549-54 PMID: 2748838
  71. Procedures for setting normal values.
    Neurology. 1995 Jan;45(1):17-23 PMID: 7824110
  72. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.
    J Cereb Blood Flow Metab. 2005 Nov;25(11):1528-47 PMID: 15944649
  73. Unified segmentation.
    Neuroimage. 2005 Jul 1;26(3):839-51 PMID: 15955494
  74. The Clinical Dementia Rating (CDR): current version and scoring rules.
    Neurology. 1993 Nov;43(11):2412-4 PMID: 8232972
  75. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging.
    Neurobiol Aging. 1996 May-Jun;17(3):365-71 PMID: 8725897
  76. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment.
    Neuroreport. 2002 Oct 28;13(15):1939-43 PMID: 12395096
  77. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease.
    Neuroimage. 2001 Aug;14(2):298-309 PMID: 11467904
  78. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Brain. 2006 Nov;129(Pt 11):2856-66 PMID: 16854944
  79. Phases of A beta-deposition in the human brain and its relevance for the development of AD.
    Neurology. 2002 Jun 25;58(12):1791-800 PMID: 12084879
  80. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
    Ann Neurol. 2004 Mar;55(3):306-19 PMID: 14991808
  81. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease.
    Cereb Cortex. 1991 Jan-Feb;1(1):103-16 PMID: 1822725
Article Info
Journal
Brain : a journal of neurology
Abbr.
Brain
ISSN
1460-2156
Published
2008-03-00
Epub
2008-00-07
Pages
665-80
Language
English
Region
England
NLM ID
0372537
PMCID
PMC2730157
Subset
IM
Grants
NIA NIH HHS · P50 AG16574 · United States
NCRR NIH HHS · C06 RR018898 · United States
NIA NIH HHS · R01 AG11378 · United States
NIA NIH HHS · R01 AG011378 · United States
NIA NIH HHS · R01 AG011378-15 · United States
NIA NIH HHS · U01 AG06786 · United States
NIA NIH HHS · U01 AG006786 · United States
NIA NIH HHS · U01 AG006786-23 · United States
NIA NIH HHS · P50 AG016574 · United States
NIA NIH HHS · AG11378 · United States
NIA NIH HHS · P50 AG016574-100004 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]